Acronym:
JTJN OVARIAN
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
Cancer Type | Gynaecological | ||
---|---|---|---|
Trial Type | Treatment | ||
Phase | Phase II | Tumour Stream | Ovarian |
Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced |
Sex | Female | Anticipated Start Date | |
Molecular Target | Anticipated End Date |
Cancer Type | Gynaecological |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Female |
Molecular Target | |
Tumour Stream | Ovarian |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | |
Anticipated End Date |
Trial Summary
A phase II study of rexasertib in platinum-resistant or refractory recurrent ovarian cancer.
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
---|---|---|---|---|---|
Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Ganessan Kichenadasse | Recruiting |